Benjamin Schleich

Outcomes of de novo belatacept‐based immunosuppression regimen and avoidance of calcineurin inhibitors in recipients of kidney allografts at higher risk for underutilization

D. Serur, Vikram Wadhera, Y. Yushkov, 2022, Nephrology.